Testing a yellow fever vaccine in healthy adults
Yellow Fever Human Infection Model With YF-17D
NA · Leiden University Medical Center · NCT05901454
This study is testing a yellow fever vaccine in healthy adults aged 18-50 to see if it is safe and effective for people who are at risk but can't get vaccinated.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years to 50 Years |
| Sex | All |
| Sponsor | Leiden University Medical Center (other) |
| Locations | 1 site (Leiden) |
| Trial ID | NCT05901454 on ClinicalTrials.gov |
What this trial studies
This study investigates the safety and efficacy of the YF-17D yellow fever vaccine in healthy adults aged 18-50 years. It aims to address the lack of antiviral treatments for yellow fever, focusing on individuals who are at risk but cannot be vaccinated due to contraindications. The study will involve administering the vaccine and monitoring participants for any adverse effects or immune responses. The ultimate goal is to develop effective treatment options for those unprotected against yellow fever infection.
Who should consider this trial
Good fit: Ideal candidates for this study are healthy adults aged 18-50 years who are at risk of yellow fever infection.
Not a fit: Patients with contraindications to the YF-17D vaccine, such as immune deficiencies or previous vaccinations, will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to life-saving treatment options for individuals at risk of yellow fever who cannot be vaccinated.
How similar studies have performed: Other studies have explored yellow fever vaccination and its effects, but this specific approach to treatment in unvaccinated individuals is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * age 18-50 years Exclusion Criteria: * contraindication to receive YF-17D (immune deficiency, thymus illness) * previous YF vaccination * pregnancy * chicken egg allergy * hypersensitivity to any other substance in the YF-17D vaccine * interval of \< 4 weeks of another live attenuated vaccine
Where this trial is running
Leiden
- Leiden University Medical Center — Leiden, Netherlands (RECRUITING)
Study contacts
- Principal investigator: Anna HE Roukens, MD PhD — Leiden University Medical Center
- Study coordinator: Anna H Roukens, MD, PhD
- Email: a.h.e.roukens@lumc.nl
- Phone: +31715262613
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Yellow Fever